Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

Dow Jones

06/17

0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company "looks like it could continue to deliver mid-teen EPS growth." (mike.cherney@wsj.com)

(END) Dow Jones Newswires

June 16, 2025 22:15 ET (02:15 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544360933"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544360933\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544360933?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544360933","market":"other","top_or_hot":-1,"title":"Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" (mike.cherney@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2025 22:15 ET (02:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHigher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-06-17 10:15</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" (mike.cherney@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2025 22:15 ET (02:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡萊爾夥伴","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2544360933","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544360933","pubTimestamp":1750126500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED"},"translate_title":"CSL的Andembry提供更高的利润率将提高盈利——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1},"content_text":"0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" (mike.cherney@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2025 22:15 ET (02:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}